In view of these results, inhibiting DNA-PKcs activation and/or enhancing MOTS-c expression are potential therapeutic approaches to prevent JNK-dependent profilin phosphorylation and protect the endothelial barrier against endotoxemia. The gene discussed is MAPK8; the disease is serum lipopolysaccharide activity.